MAC 124 OCD Action Website Leaflet V0.2
MAC Clinical Research is running a clinical research trial at their sites at Leeds, Teesside, Cannock, Liverpool, Blackpool and Barnsley sites studying a potential new treatment for OCD. The study drug, Troriluzole, targets the glutamatergic signalling pathway in the brain. Studies suggest that the glutamatergic signalling pathway in the brain is overactive in people with OCD.
The study will run for approximately four months. This includes taking the study medication daily for ten weeks and requires 7 visits to the clinic for check-ups to see if your OCD symptoms improve and how well you cope with taking the drug (any side-effects). Upon completion of the study participants will be offered an opportunity to enter the Open Label Extension study and receive the study medication free of charge for 1 year.
To be eligible to take part in this study you must be between 18 and 65, have been diagnosed with OCD or have had symptoms of OCD (even if you don’t have a formal diagnosis) for at least a year and be taking an OCD medication that you do not feel is fully helping with your condition. Further restrictions may apply depending on your medical history. If you take part in the study, you will be compensated for your time and reasonable travel costs will be covered.
If you are interested please call UK Freephone: 0800 917 7679